Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
LUND (SWEDEN) - Philipp von Hugo, member of the board of directors of Immunovia AB (publ) ("Immunovia" or the "Company"), has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.
Philipp von Hugo, who has served as board member of Immunovia since the annual general meeting in 2022, has on 5 May 2023 at his own request with immediate effect, notified his resignation from his position as board member of Immunovia and consequently declines re-election, at the annual general meeting on 26 May 2023.
The Nomination Committee of the Company has been informed of his decision.
"We thank Philipp for his commitment to the board and wish him the best in his future engagements", comments the chair of the Board of Directors Carl Borrebaeck.
FOR MORE INFORMATION, PLEASE CONTACT:
Carl Borrebaeck
Chair of the Board of Directors
carl.borrebaeck@immun.lth.se
+46 70 821 83 30
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
ABOUT IMMUNOVIA
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. The company is headquartered in Lund, Sweden. Immunovia's shares are listed on Nasdaq Stockholm. For more information please visit www.immunovia.com.